Investor Relations

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology.

Latest News

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

View Press Release

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

View Press Release

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

View Press Release
Company Presentation

Latest Presentation

Company Presentation

December 2024 Fact Sheet

Fact Sheet

December 2024 Fact Sheet

Latest Event

Q4 2024 Results Conference Call

Company Overview

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology. Its liquid-nitrogen based systems use ultra cold temperatures to destroy tumors by freezing them. Supported by clinical experience across multiple areas of cancer care, IceCure is opening the door for quick, convenient office-based and CT room procedures. Cryoablation - It's your choice.

Latest Financial Results

FY 2024

Fiscal Year Ended Dec 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Stock Snapshot

IR Contacts

Headquarters

IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
Caesarea 3079504
Israel
T: +972-4-623-0333
F: +972-4-623-0222
investors@icecure-medical.com

Investor Relations

EVC Group
Michael Polyviou
Todd Kehrli
T: +1-732-933-2755
investors@icecure-medical.com
https://www.evcgroup.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com